CD22: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of CD22. The page also collects GeneMedi’s different modalities and formats products for CD22 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the CD22 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022]

Target ID

GM-T37539

Target Name

CD22

Gene ID

933

Gene Official Name

CD22

Gene Alias

SIGLEC-2, SIGLEC2

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index

Pre-made CD22-specific INN-index biosimilar (antibody&conjugates)-Moxetumomab, inotuzumab ozogamicin, Inotuzumab, pinatuzumab vedotin, Epratuzumab, bectumomab, Pinatuzumab, Suciraslimab, moxetumomab pasudotox

Anti-CD22 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
Epratuzumab
NA
CD22
Whole mAb
Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
Inotuzumab
NA
CD22
Whole mAb ADC
Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
Moxetumomab
NA
CD22
Fv Fusion
Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
Pinatuzumab
NA
CD22
Whole mAb ADC
Pre-Made Suciraslimab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
Suciraslimab
NA
CD22
Whole mAb
Pre-Made Bectumomab Biosimilar, Fab Fusion, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody
bectumomab
NA
CD22
Fab Fusion
Pre-Made Inotuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
inotuzumab ozogamicin
NA
CD22
Whole mAb ADC
Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A
moxetumomab pasudotox
NA
CD22
Fusion Protein
Pre-Made Pinatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
pinatuzumab vedotin
NA
CD22
Whole mAb ADC

Anti-CD22/ SIGLEC-2/ SIGLEC2 antibody for FACS & in-vivo assay| GMab

Pre-made anti-CD22 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD22 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-CD22 monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody